{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:33:59Z","timestamp":1789450439487,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemiplegic migraine (HM) is a rare and disabling subtype of migraine with aura characterized by reversible motor weakness. Preventive treatment remains challenging, as patients with HM are systematically excluded from RCTs. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) have shown effectiveness in migraine with typical aura, but evidence in HM is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and quantitative synthesis followed PRISMA guidelines. PubMed, Scopus, and Web of Science were searched for studies reporting patients with HM treated with anti-CGRP mAbs. Individual patient data were extracted, and pooled analyses were conducted for changes in monthly headache days (MHDs), days with aura, and Migraine Disability Assessment (MIDAS) score from baseline to three months. Risk of bias was assessed using the GRADE approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six studies (four case series and two case reports), including 13 patients, met the inclusion criteria. MHDs decreased from 18 (IQR 15\u201325) at baseline to 9 (IQR 3\u201320) at three months; however, the numerical decrease was not statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.077). Median monthly days with aura decreased from 3 (IQR 2\u20138) to 0.6 (IQR 0\u20132.3;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018), and the MIDAS score decreased from 88 (IQR 66\u2013154) to 28 (IQR 5\u201374;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018). Ten patients (83%) achieved\u2009&gt;\u200950% reduction in MHDs and aura frequency, and nine (75%)\u2009&gt;\u200950% MIDAS reduction. No adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the overall evidence certainty is very low, anti-CGRP mAbs appear to reduce aura burden and migraine-related disability in HM with good tolerability, supporting the need for prospective multicenter studies and registries to confirm their effectiveness and safety in this rare, highly disabling condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-026-02283-5","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:45:46Z","timestamp":1769791546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Marina","family":"Romozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0192-5430","authenticated-orcid":false,"given":"Masahito","family":"Katsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Tosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Vollono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2283_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38(1):1\u2013211","DOI":"10.1177\/0333102417738202"},{"issue":"5","key":"2283_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1474-4422(11)70048-5","volume":"10","author":"MB Russell","year":"2011","unstructured":"Russell MB, Ducros A (2011) Sporadic and Familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 10(5):457\u2013470","journal-title":"Lancet Neurol"},{"issue":"21","key":"2283_CR3","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1212\/WNL.0b013e3182752cb8","volume":"79","author":"F Riant","year":"2012","unstructured":"Riant F, Roze E, Barbance C, M\u00e9neret A, Guyant-Mar\u00e9chal L, Lucas C et al (2012) PRRT2 mutations cause hemiplegic migraine. Neurology 79(21):2122\u20132124","journal-title":"Neurology"},{"issue":"7","key":"2283_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/jnnp-2020-322850","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Rispoli MG, Pellegrino N, Graziosi A, Rotondo E, Napoli C et al (2020) Diagnostic and therapeutic aspects of hemiplegic migraine. J Neurol Neurosurg Psychiatry 91(7):764\u2013771","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2283_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s10194-021-01297-5","volume":"22","author":"M Romozzi","year":"2021","unstructured":"Romozzi M, Primiano G, Rollo E, Travaglini L, Calabresi P, Servidei S et al (2021) CACNA1A-p.Thr501Met mutation associated with Familial hemiplegic migraine: a family report. J Headache Pain 22(1):85","journal-title":"J Headache Pain"},{"issue":"1","key":"2283_CR6","doi-asserted-by":"publisher","first-page":"fcae447","DOI":"10.1093\/braincomms\/fcae447","volume":"7","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Spartano S, L\u2019Erario FF, Iannone LF, Trigila V, Gentile A et al (2025) Clinical characterization of a novel ATP1A2 p.Gly615Glu mutation in nine family members with Familial hemiplegic migraine. Brain Commun 7(1):fcae447","journal-title":"Brain Commun"},{"issue":"5","key":"2283_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.5692\/clinicalneurol.cn-002070","volume":"65","author":"D Danno","year":"2025","unstructured":"Danno D, Shanahan P, Matharu M (2025) Clinical characteristics of hemiplegic migraine: a clinical study of 163 cases in a tertiary care headache centre. Rinsho Shinkeigaku 65(5):338\u2013351","journal-title":"Rinsho Shinkeigaku"},{"issue":"1","key":"2283_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-025-02011-5","volume":"26","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Calabresi P (2025) Is there a role of calcitonin gene-related peptide in cortical spreading depression mechanisms?\u2013 argument pro. J Headache Pain 26(1):90","journal-title":"J Headache Pain"},{"issue":"8","key":"2283_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/03331024221077646","volume":"42","author":"M Ashina","year":"2022","unstructured":"Ashina M, McAllister P, Cady R, Hirman J, Ettrup A (2022) Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: post hoc analysis of PROMISE-1 and PROMISE-2. Cephalalgia 42(8):696\u2013704","journal-title":"Cephalalgia"},{"issue":"1","key":"2283_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-023-01560-x","volume":"24","author":"S Ashina","year":"2023","unstructured":"Ashina S, Melo-Carrillo A, Toluwanimi A, Bolo N, Szabo E, Borsook D et al (2023) Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders. J Headache Pain 24(1):26","journal-title":"J Headache Pain"},{"issue":"13","key":"2283_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/03331024221111526","volume":"42","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, De Cesaris F, Ferrari A, Benemei S, Fattori D, Chiarugi A (2022) Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. Cephalalgia 42(13):1323\u20131330","journal-title":"Cephalalgia"},{"key":"2283_CR12","doi-asserted-by":"crossref","unstructured":"Romozzi M, Burgalassi A, Vollono C, Albanese M, Vigani G, De Cesaris F et al (2024) Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment. Confinia Cephalalgica. 34(1)","DOI":"10.4081\/cc.2024.15762"},{"key":"2283_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"1","key":"2283_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Reviews 5(1):210","journal-title":"Syst Reviews"},{"issue":"6","key":"2283_CR15","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s10072-024-07980-0","volume":"46","author":"P Antenucci","year":"2025","unstructured":"Antenucci P, Pes F, Cesnik E, Capone JG, Padroni M (2025) A case of sporadic hemiplegic migraine treated with eptinezumab: should we consider anti-CGRP antibodies for selected patients? Neurol Sci 46(6):2883\u20132885","journal-title":"Neurol Sci"},{"issue":"11","key":"2283_CR16","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1007\/s10072-024-07665-8","volume":"45","author":"M D\u2019Apolito","year":"2024","unstructured":"D\u2019Apolito M, Rispoli MG, Ajdinaj P, Travaglini D, Bonanni L (2024) Sporadic hemiplegic migraine with novel missense mutation in the SCN1A gene and positive response to anti-CGRP antibody: a case report. Neurol Sci 45(11):5535\u20135537","journal-title":"Neurol Sci"},{"key":"2283_CR17","doi-asserted-by":"crossref","unstructured":"Danno D, Ishizaki K, Kikui S, Takeshima T (2023) Treatment of hemiplegic migraine with anti-calcitonin gene-related peptide monoclonal antibodies: a case series in a tertiary-care headache center. Headache","DOI":"10.1111\/head.14591"},{"issue":"2","key":"2283_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/head.14840","volume":"65","author":"C Sottani","year":"2025","unstructured":"Sottani C, Di Lazzaro G, Calabresi P, Pomponi MG, Tiziano FD, Bentivoglio AR et al (2025) Efficacy of galcanezumab in proline-rich transmembrane protein 2 (PRRT2)-associated Familial hemiplegic migraine: A case series. Headache 65(2):377\u2013381","journal-title":"Headache"},{"key":"2283_CR19","doi-asserted-by":"publisher","first-page":"1579203","DOI":"10.3389\/fneur.2025.1579203","volume":"16","author":"M H\u00e9ja","year":"2025","unstructured":"H\u00e9ja M, Ol\u00e1h L (2025) Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature. Front Neurol 16:1579203","journal-title":"Front Neurol"},{"issue":"10","key":"2283_CR20","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1007\/s00415-024-12602-y","volume":"271","author":"E Indelicato","year":"2024","unstructured":"Indelicato E, Nachbauer W, Amprosi MS, Maier S, Unterberger I, Delazer M et al (2024) Natural history of non-polyglutamine CACNA1A disease in Austria. J Neurol 271(10):6618\u20136627","journal-title":"J Neurol"},{"issue":"1","key":"2283_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-022-00410-3","volume":"12","author":"H Igarashi","year":"2023","unstructured":"Igarashi H, Shibata M, Ozeki A, Matsumura T (2023) Galcanezumab effects on migraine severity and symptoms in Japanese patients with episodic migraine: secondary analysis of a phase 2 randomized trial. Neurol Ther 12(1):73\u201387","journal-title":"Neurol Ther"},{"issue":"2","key":"2283_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaneurol.2021.4678","volume":"79","author":"M Ashina","year":"2022","unstructured":"Ashina M, Goadsby PJ, Dodick DW, Tepper SJ, Xue F, Zhang F et al (2022) Assessment of erenumab safety and efficacy in patients with migraine with and without aura: A secondary analysis of randomized clinical trials. JAMA Neurol 79(2):159\u2013168","journal-title":"JAMA Neurol"},{"issue":"1","key":"2283_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-021-01344-1","volume":"22","author":"A Straube","year":"2021","unstructured":"Straube A, Stude P, Gaul C, Schuh K, Koch M (2021) Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain 22(1):133","journal-title":"J Headache Pain"},{"key":"2283_CR24","doi-asserted-by":"publisher","first-page":"107169","DOI":"10.1016\/j.clineuro.2022.107169","volume":"214","author":"D Mahovi\u0107","year":"2022","unstructured":"Mahovi\u0107 D, Bra\u010di\u0107 M, Jaku\u0161 L, Vukovic Cvetkovic V, Krpan M (2022) Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience. Clin Neurol Neurosurg 214:107169","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"2283_CR25","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00415-021-10546-1","volume":"268","author":"E Matteo","year":"2021","unstructured":"Matteo E, Pensato U, Favoni V, Giannini G, Pierangeli G, Cevoli S (2021) Do anti-CGRP drugs have a role in migraine aura therapy? J Neurol 268(6):2273\u20132274","journal-title":"J Neurol"},{"key":"2283_CR26","doi-asserted-by":"crossref","unstructured":"Albanese M, Mercuri NB (2022) Could the new anti-CGRP monoclonal antibodies be effective in migraine aura? Case reports and literature review. J Clin Med, 11(5)","DOI":"10.3390\/jcm11051228"},{"issue":"3","key":"2283_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0333102419896760","volume":"40","author":"R Noseda","year":"2020","unstructured":"Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F et al (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 40(3):229\u2013240","journal-title":"Cephalalgia"},{"issue":"6","key":"2283_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Reviews Neurol 14(6):338\u2013350","journal-title":"Nat Reviews Neurol"},{"issue":"10","key":"2283_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/0333102419844711","volume":"39","author":"KW Johnson","year":"2019","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP (2019) Peripheral and central nervous system distribution of the CGRP neutralizing antibody [(125)I] galcanezumab in male rats. Cephalalgia 39(10):1241\u20131248","journal-title":"Cephalalgia"},{"issue":"3","key":"2283_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0333102418774299","volume":"39","author":"LN Close","year":"2019","unstructured":"Close LN, Eftekhari S, Wang M, Charles AC, Russo AF (2019) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 39(3):428\u2013434","journal-title":"Cephalalgia"},{"issue":"2","key":"2283_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644","journal-title":"Physiol Rev"},{"issue":"46","key":"2283_CR32","doi-asserted-by":"publisher","first-page":"18985","DOI":"10.1073\/pnas.1215435109","volume":"109","author":"A Tozzi","year":"2012","unstructured":"Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, Pisani A et al (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A 109(46):18985\u201318990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2283_CR33","unstructured":"Eftekhari S, Kechechyan GM, Faas G, Charles A (eds) (2017) The CGRP receptor antagonist olcegepant modulates cortical spreading depression in vivo. Cephalalgia"},{"key":"2283_CR34","doi-asserted-by":"crossref","unstructured":"Basedau H, Sturm LM, Mehnert J, Peng KP, Schellong M, May A (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study. eLife. 11","DOI":"10.7554\/eLife.77146"},{"issue":"2","key":"2283_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0333102416684344","volume":"38","author":"H Ashina","year":"2018","unstructured":"Ashina H, Schytz HW, Ashina M (2018) CGRP in human models of primary headaches. Cephalalgia 38(2):353\u2013360","journal-title":"Cephalalgia"},{"issue":"10","key":"2283_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30(10):1179\u20131186","journal-title":"Cephalalgia"},{"issue":"1","key":"2283_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s10194-023-01656-4","volume":"24","author":"HM Al-Khazali","year":"2023","unstructured":"Al-Khazali HM, Ashina H, Wiggers A, Rose K, Iljazi A, Christensen RH et al (2023) Calcitonin gene-related peptide causes migraine aura. J Headache Pain 24(1):124","journal-title":"J Headache Pain"},{"issue":"1","key":"2283_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0333102420956692","volume":"41","author":"C Altamura","year":"2021","unstructured":"Altamura C, Viticchi G, Fallacara A, Costa CM, Brunelli N, Fiori C et al (2021) Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura. Cephalalgia 41(1):90\u201398","journal-title":"Cephalalgia"},{"issue":"3","key":"2283_CR39","doi-asserted-by":"publisher","first-page":"033310242311521","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler E-M, Puledda F, Haghdoost F, Lebedeva ER, Diener H-C (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia 43(3):03331024231152169","journal-title":"Cephalalgia"},{"key":"2283_CR40","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2023","unstructured":"Sun W, Li Y, Xia B, Chen J, Liu Y, Pang J et al (2023) Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. Front Pharmacol 14:1257282","journal-title":"Front Pharmacol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02283-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:25:37Z","timestamp":1781630737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02283-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02283-5","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}